NSW based Medlab Clinical (ASX:MDC) announces it has achieved record sales of its NanaBis product in the first quarter of this year.
NanaBis is a product containing 1:1 ratios of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), delivered in a sub-micron spray applied to the oro-buccal membrane; i.e. the inside of the cheek. NanaBis is currently not listed on the Australian Register of Therapeutic Goods (ARTG), but is in clinical trial and available under the Therapeutic Goods Administration’s (TGA’s) Special Access Scheme (SAS).
In a report published Monday, Medlab says the company saw an increase of approximately 26% over the previous best quarter and 217% over the previous corresponding period for NanaBis sales. The March quarter was the first time sales volume reached over 2,000 bottles of the product.
02228566